10x Genomics (TXG) Stock Rally Leans On Margin Gains And Cash

10x Genomics stock jumped 14.1% to about US$52 after its Q2 report, and the move appears to reflect sentiment rather than a sudden profit breakthrough. The company still reported a loss per share and quarterly revenue of US$151 million, so the market is effectively reacting to the quality of the loss, not the absence of it.

The key focus for traders is margin and balance sheet resilience. Gross margin improved to roughly 74%, and cash and marketable securities stood at US$552 million. Today’s surge is being interpreted as a sign that these cushions may give 10x Genomics more time to pursue its technology strategy.

Is 10x Genomics stock trading at a genuine discount, or is it simply viewed as a high priced growth story? See how the current price, DCF gap, and rich P/S multiple compare in the valuation analysis for 10x Genomics

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$151.0 million vs. US$172.9 million (revenue declined year over year)
• Net Income, Q2 2026 vs. Q2 2025: loss of US$17.9 million vs. profit of US$34.5 million (swung from profit to loss)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.14 per share vs. profit of US$0.28 per share (moved from positive to negative earnings per share)
• Gross Margin, Q2 2026: approximately 74% (management highlighted improved margin quality for 10x Genomics in the quarter)

If you prefer clean, visual charts over scrolling through detailed earnings tables and footnotes, you can get an overview of 10x Genomics' valuation with an at a glance view by checking out the company report for 10x Genomics.

Evaluating Whether 10x Genomics’ Growth Story Is Back On Track

Bulls argue that 10x Genomics is shifting from a lumpy instrument cycle toward a higher quality mix of recurring consumables, software and multiomic workflows. Q2 gives some support to that view. Total consumables grew 7% year over year, with Single Cell consumables up 3% and Spatial consumables up 16%. That sits alongside a 47% decline in instrument revenue, so usage is holding up even as customers pause on new hardware.

The growth story around Atera also has early proof points. Management described order momentum that already exceeds the plan to ship about 40 Atera units in 2026, even though those shipments are weighted to Q4. The Proteintech Genomics acquisition and raised 2026 revenue guidance to US$610m to US$630m indicate that the company is aligning operations behind multiomics and oncology workloads rather than only outlining a potential future inflection.

Compare that internal momentum with external expectations and see whether Wall Street thinks 10x Genomics can sustain it by checking the consensus price target analysis for 10x Genomics.

10x Genomics Bears Still See Missed Earnings Milestones

The bearish view on 10x Genomics is that a heavy cost base, pressured instruments and funding sensitive customers could keep the business stuck in low growth with recurring losses. Q2 does not fully disprove that. Revenue excluding the Takara settlement grew only about 3% and instrument sales fell 47%, which lines up with concerns that big ticket hardware tied to academic and pharma budgets is under strain.

Critically, the structural cost worry is still in play. Operating expenses reached US$132.1m and management described them as roughly flat after adjusting for settlements. That is a high bar relative to US$151m of quarterly revenue and it left the company in a loss position again. Guidance of 2% to 5% growth for 2026 is an improvement, but it falls short of the stronger reacceleration bears considered necessary to comfortably cover this cost base.

After another quarter of losses and soft instrument demand, it is fair to ask if these pressures are isolated. Review the independent risk analysis for 10x Genomics which shows 2 important warning signs to see whether our risk scoring flags deeper structural issues you might have overlooked.

Take Control Of Your Next Move

If the mix of margin resilience and ongoing losses at 10x Genomics has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry point. Once you are invested, use the Portfolio Command Center to keep your holdings organised and surface only the most important alerts, so short term price swings do not drown out key developments. For longer term conviction, tap into the Community to see how other investors are interpreting the same earnings, guidance and risk signals. That way you can spot potential catalysts or red flags early and stay a step ahead of the market.

Seeking Alternatives Beyond 10x Genomics?

Fresh stock ideas move fast and early momentum can leave latecomers caught chasing. Scan curated picks now while they are still under the radar for now and act now.

• Catch potential breakout compounding stories before the crowd studies them by running your filters through the curated 19 high quality undiscovered gems that focus on fundamentals investors often overlook.
• Lock onto companies where cash strength may support momentum by scanning the curated list of solid balance sheet and fundamentals stocks (49 results) that highlight resilience when markets turn choppy.
• Ride structural demand shifts in critical materials by zeroing in on the curated 28 best rare earth metal stocks that spotlight producers tied to long term technology build outs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com